Indiva (TSXV:NDVA.H) - Hisse Senedi Fiyatı, Haberler ve Analizler

NDVA.H Stoklara Genel Bakış

Engages in the production, processing, and sale of cannabis and cannabis related products in Canada. Daha fazla detay

NDVA.H temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	1/6
Temettüler	0/6

Ödüller

Kazançlar son 5 yılda yılda 6.8% oranında arttı

Risk Analizi

Hisse senetleri oldukça likit değildir

1 yıldan az nakit akışı var

Anlamlı bir piyasa değeri yok ( CA$6M )

Negatif hissedar öz sermayesi

+ 1 daha fazla risk

Indiva Limited Rakipler

Delivra Health Brands

TSXV:DHB

CA$6.3m

StateHouse Holdings

CNSX:STHZ

CA$7.7m

Blueberries Medical

CNSX:BBM

CA$6.0m

Appili Therapeutics

TSX:APLI

CA$4.2m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Indiva
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	CA$0.03
52 Haftanın En Yüksek Seviyesi	CA$0.13
52 Haftanın En Düşük Seviyesi	CA$0.03
Beta	1.08
11 Aylık Değişim	0%
3 Aylık Değişim	-14.29%
1 Yıllık Değişim	-45.45%
33 Yıllık Değişim	-93.75%
5 Yıllık Değişim	-90.63%
Halka arzdan bu yana değişim	-97.60%

Son Haberler & Güncellemeler

Indiva Limited's (CVE:NDVA) Subdued P/S Might Signal An Opportunity

May 28

Recent updates

Indiva Limited's (CVE:NDVA) Subdued P/S Might Signal An Opportunity

May 28

Indiva Limited (CVE:NDVA) Stock Catapults 33% Though Its Price And Business Still Lag The Industry

Sep 29

Hissedar Getirileri

	NDVA.H	CA Pharmaceuticals	CA Pazar
7D	0%	-5.2%	1.3%
1Y	-45.5%	-23.4%	23.1%

Getiri vs. Endüstri: NDVA.H geçen yıl % -23.4 oranında getiri sağlayan Canadian Pharmaceuticals sektörünün gerisinde kaldı.

Getiri vs Piyasa: NDVA.H geçen yıl % 23.1 oranında getiri sağlayan Canadian Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is NDVA.H's price volatile compared to industry and market?
NDVA.H volatility
NDVA.H Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	12.0%
Market Average Movement	8.3%
10% most volatile stocks in CA Market	17.8%
10% least volatile stocks in CA Market	2.9%

İstikrarlı Hisse Senedi Fiyatı: NDVA.H hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: NDVA.H 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
n/a	n/a	Niel Marotta	www.indiva.com

Indiva Limited Temel Bilgiler Özeti

Indiva'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
NDVA.H temel i̇stati̇sti̇kler
Piyasa değeri	CA$5.86m
Kazançlar(TTM)	-CA$4.44m
Gelir(TTM)	CA$37.49m

0.2x

P/S Oranı

-1.3x

F/K Oranı

NDVA.H aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
NDVA.H gelir tablosu (TTM)
Gelir	CA$37.49m
Gelir Maliyeti	CA$26.54m
Brüt Kâr	CA$10.95m
Diğer Giderler	CA$15.39m
Kazançlar	-CA$4.44m

Son Raporlanan Kazançlar

Mar 31, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.023
Brüt Marj	29.21%
Net Kâr Marjı	-11.83%
Borç/Özkaynak Oranı	-1,692.6%

NDVA.H uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

NDVA.H Stoklara Genel Bakış

Ödüller

Risk Analizi

Indiva Limited Rakipler

TSXV:DHB

CA$6.3m

CNSX:STHZ

CA$7.7m

CNSX:BBM

CA$6.0m

TSX:APLI

CA$4.2m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

SNDL Inc. (NasdaqCM:SNDL) completed the acquisition of remaining majority stake in Indiva Limited (TSXV:NDVA.H).

Insufficient new directors

Indiva Limited Announces Resignation of Rachel Goldman from the Board

New major risk - Financial position

Indiva Limited's (CVE:NDVA) Subdued P/S Might Signal An Opportunity

Indiva Limited Provides Earnings Guidance for the Second Quarter of 2024

Recent updates

SNDL Inc. (NasdaqCM:SNDL) completed the acquisition of remaining majority stake in Indiva Limited (TSXV:NDVA.H).

Insufficient new directors

Indiva Limited Announces Resignation of Rachel Goldman from the Board

New major risk - Financial position

Indiva Limited's (CVE:NDVA) Subdued P/S Might Signal An Opportunity

Indiva Limited Provides Earnings Guidance for the Second Quarter of 2024

Indiva Limited to Report Q1, 2024 Results on May 23, 2024

Indiva Limited Provides Earnings Guidance for the First Quarter and Fiscal Year 2024

New major risk - Negative shareholders equity

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Indiva Limited to Report Q4, 2023 Results on Apr 25, 2024

New major risk - Market cap size

Insufficient new directors

Indiva Limited announced that it expects to receive CAD 4.312 million in funding

Indiva Limited announced that it expects to receive CAD 4 million in funding

Price target increased by 15% to CA$0.15

Indiva Limited Provides Revenue Guidance for Fourth Quarter of 2023

Third quarter 2023 earnings released: CA$0.005 loss per share (vs CA$0.018 loss in 3Q 2022)

Indiva Limited to Report Q3, 2023 Results on Nov 21, 2023

Indiva Limited (CVE:NDVA) Stock Catapults 33% Though Its Price And Business Still Lag The Industry

Is Indiva (CVE:NDVA) Using Debt In A Risky Way?

Second quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.017 loss in 2Q 2022)

Indiva Limited to Report Q2, 2023 Results on Aug 29, 2023

Indiva Limited Launches No Future Gummies and Vapes

New minor risk - Shareholder dilution

New major risk - Share price stability

Indiva Limited announced that it expects to receive CAD 2.155617 million in funding from Canopy Growth Corporation

Indiva Limited Provides Revenue Guidance for the Second Quarter of 2023

Indiva Limited, Annual General Meeting, Jul 18, 2023

Indiva Limited to Report Q1, 2023 Results on May 16, 2023

Is Indiva (CVE:NDVA) A Risky Investment?

Full year 2022 earnings: EPS and revenues miss analyst expectations

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to CA$0.50

Indiva Limited to Report Q3, 2022 Results on Nov 22, 2022

Indiva Limited Provides Revenue Guidance for the Second Half and Full Year of 2022

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Indiva Limited to Report Q2, 2022 Results on Aug 16, 2022

Indiva Limited Provides Revenue Guidance for the Second Quarter of 2022

Consensus estimates of losses per share improve by 62%

Indiva Limited Provides Revenue Guidance for the Second Quarter of 2022

Indiva Limited to Report Q1, 2022 Results on May 19, 2022

Price target decreased to CA$0.60

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Indiva Limited Provides Net Revenue Guidance for the First Quarter of 2022

Indiva Limited, Annual General Meeting, Jun 23, 2022

Indiva Limited to Report Fiscal Year 2021 Results on Apr 26, 2022

Is Indiva (CVE:NDVA) Using Too Much Debt?

Indiva Limited Launches New Cannabis Edible Designed for MicroDosing

Indiva Launches New Cannabis Edible Formulated for Night-Time Use

Third quarter 2021 earnings released: CA$0.047 loss per share (vs CA$0.035 loss in 3Q 2020)

Would Indiva (CVE:NDVA) Be Better Off With Less Debt?

Second quarter 2021 earnings released: CA$0.01 loss per share (vs CA$0.029 loss in 2Q 2020)

Indiva Limited Provides Revenue Guidance for the Second Half of 2021

First quarter 2021 earnings released: CA$0.025 loss per share (vs CA$0.029 loss in 1Q 2020)

Full year 2020 earnings released: CA$0.16 loss per share (vs CA$0.14 loss in FY 2019)

Indiva Limited to Introduce Two New Bhang Chocolate Flavours Nationally in Second Quarter of 2021

Indiva Limited Ships Wana Quick Gummies

Indiva Limited Appoints Russell Wilson to the Board of Directors